Regeneron anti-cholesterol drug effective in clinical trials

By Leif Skodnick

1 Comment

The Greenburgh-based pharmaceutical company announces its drug alirocumab reduced levels of “bad cholesterol” by 61 percent in a study.

This content is for Westfair Online members only. Please login to view this content. Become a member by Registering Here. If you would prefer to start with a 12 week free trial, Click Here.


About the author

Leif Skodnick
Leif Skodnick is a former reporter for Westfair Communications. He is a graduate of Columbia Journalism School, Mississippi College School of Law, and St. Lawrence University.

Related Articles